Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases — kidney, liver and lung fibrosis — the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
A new Northwestern Medicine study has newly identified a trigger of some fibrotic diseases and an experimental compound to treat it.
Fibrosis — a progressive scarring and hardening of internal organs — is estimated to cause 35 to 40 percent of deaths in the world. Fibrotic diseases include diabetic kidney fibrosis, alcoholic liver cirrhosis, hepatitis C, pulmonary fibrosis and nonalcoholic fatty liver disease, which may lead to fibrosis of the liver, the leading cause of liver transplant.
In one subset of human fibrosis cells, scientists discovered a delinquent gang of molecules that continually shouted at an immune receptor — the antennae on the cell — to produce scar tissue instead of quieting down and allowing the scar tissue to go back to sleep.
Scientists collaborated with a University of Colorado researcher who used crystallography and computer modeling to predict a molecule that could block the receptor that leads to the uncontrolled scarring. When they tested the molecule, T53, in three different mouse models of fibrosis, the abnormality was significantly reversed.
“Our study opens a new door into fibrosis by looking at it as an aberrant innate immune response and suggesting a novel approach to treat it,” said senior author Dr. John Varga, director of the Northwestern Scleroderma Program and the John and Nancy Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg School of Medicine.
The paper was published July 12 in the Journal of Clinical Investigation Insight.
“The leading cause of liver failure in western world is obesity and that’s because of liver fibrosis,” Varga said. “In the U.S., many of these diseases are lifestyle or age dependent. As we get fatter or older, they get worse.”
Most fibrotic disease likely begins as normal repair of an injury, scientists said. “But if the immune system produces too much of an initial scar, it can’t go back to normal,” Varga said. “You have an unhealed scar that keeps growing and can wipe out the entire organ.”
Not everyone’s fibrosis is caused by the same abnormality, Varga said. If the compound, T53, is eventually developed into an approved drug, it would be targeted to patients with the specific genetic signature identified in the study.
“There is an emerging direction for treating fibrosis with precision medicine,” said first author Swati Bhattacharyya, research associate professor of medicine in rheumatology and scientific director of the Scleroderma Research Laboratory at Feinberg. “Some people live with fibrotic disease for 30 years while others die in two years. We need to identify the rapid progressors from the slow progressors. That’s where precision medicine becomes really critical.”
“The results of this study are encouraging,” Varga said. “We are not saying this compound is ready to be a drug. It’s an initial compound that would need to be developed and tweaked. It would need significant funding to go to the next step.”
Learn more: Why internal scars won’t stop growing
The Latest on: Fibrosis
via Google News
The Latest on: Fibrosis
- Irish family faces deportation after son diagnosed with cystic fibrosis on April 18, 2019 at 12:13 am
An Irish family, who has been living in Australia for almost 10 years, is facing deportation after their son was diagnosed with cystic fibrosis and deemed a "burden" on the country's health system. ... […]
- Cystic Fibrosis Market 2019 by Treatment Method, Value, Size, Industry Dynamics, Regions, Top Companies Analysis and Forecast to 2023 on April 17, 2019 at 7:07 pm
Apr 17, 2019 (AB Digital via COMTEX) -- Leading players in the global cystic fibrosis market include Vertex Pharmaceuticals, AbbVie, Novartis, Pharmaxis, Forest Laboratories, Chiesi Farmaceutici, ... […]
- Cytomegalovirus May Speed Disease Progression in Cystic Fibrosis on April 17, 2019 at 2:58 pm
Patients with cystic fibrosis who had cytomegalovirus had earlier times to lung transplant referral and reaching final stages of disease. Researchers have identified a potential explanation for why ... […]
- A virus we thought was harmless to humans may worsen cystic fibrosis on April 17, 2019 at 11:05 am
People with cystic fibrosis may experience more severe bacterial infections if they carry a certain type of virus – even though the virus actually targets bacteria. The so-called filamentous ... […]
- Laps for Landon raises $7,000 for cystic fibrosis on April 17, 2019 at 8:07 am
The wind carried music across Welch Stadium, beckoning all to come support raising cystic fibrosis awareness. More than 400 Emporians of all ages, as well as members of other communities in the region ... […]
- New test could lead to personalized treatments for cystic fibrosis on April 17, 2019 at 5:59 am
Cystic fibrosis is a devastating disease caused by mutations in a specific gene, known as the CFTR gene. But not everyone with cystic fibrosis has the same symptoms or responds to drug treatments ... […]
- Scientists report new approach to reduce or prevent renal fibrosis on April 16, 2019 at 9:22 am
Renal fibrosis, the abnormal accumulation of fibrotic material within the kidney, hinders kidney function and may lead to eventual renal failure. Using genetically altered mice, researchers from ... […]
- Novel biomarkers for noninvasive diagnosis of NAFLD-related fibrosis on April 16, 2019 at 7:27 am
New Rochelle, NY, April 15, 2019--With an estimated 25% of people worldwide affected by nonalcoholic fatty liver disease (NAFLD), there is a large unmet need for accurate, noninvasive measures to ... […]
- Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells on April 16, 2019 at 2:16 am
Personalized approaches for systematically assessing ciliary beat dynamics and for drug testing would improve the challenging task of diagnosing and treating respiratory disorders. In this pilot study ... […]
via Bing News